A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials.
Ciani O, Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS.
Ciani O, et al. Among authors: bujkiewicz s.
EClinicalMedicine. 2023 Oct 17;65:102283. doi: 10.1016/j.eclinm.2023.102283. eCollection 2023 Nov.
EClinicalMedicine. 2023.
PMID: 37877001
Free PMC article.